AbbVie (DE:4AB)

XETRA:4AB

4AB

AbbVie

RESEARCH TOOLSreports

AbbVie (4AB) Stock Forecast & Price Target

26 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4AB Analyst Ratings

Moderate Buy

15 Buy

7 Hold

0 Sell

Based on 22 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€217.83

▲(21.69% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €217.83 with a high forecast of €256.36 and a low forecast of €191.20. The average price target represents a 21.69% change from the last price of €179.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"157":"€157","182":"€182","207":"€207","232":"€232","257":"€257"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":256.35947246,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€256.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":217.8283865324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€217.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":191.19786742,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€191.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[157,182,207,232,257],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.2,190.67380557384615,196.1476111476923,201.62141672153845,207.09522229538462,212.56902786923075,218.04283344307692,223.51663901692308,228.99044459076924,234.46425016461538,239.93805573846154,245.41186131230768,250.88566688615384,{"y":256.35947246,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.2,187.70987588710767,190.21975177421538,192.72962766132306,195.23950354843078,197.74937943553846,200.25925532264614,202.76913120975385,205.27900709686153,207.78888298396924,210.29875887107693,212.8086347581846,215.31851064529232,{"y":217.8283865324,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.2,185.66137441692305,186.12274883384615,186.5841232507692,187.0454976676923,187.50687208461537,187.96824650153846,188.42962091846152,188.89099533538462,189.35236975230768,189.81374416923077,190.27511858615384,190.73649300307693,{"y":191.19786742,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":188.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.399,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.565,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.174,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.857,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.412,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.495,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.034,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€256.36

Average Price Target€217.83

Lowest Price Target€191.20

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

RBC Capital

€221.7

Buy

23.86%

Upside

Reiterated

04/10/26

AbbVie (ABBV) Receives a Buy from RBC Capital

Vamil Divan

Guggenheim

€180.42→€212.32

Buy

18.62%

Upside

Reiterated

04/10/26

AbbVie price target raised to $249 from $242 at GuggenheimAbbVie price target raised to $249 from $242 at Guggenheim

Carter Gould

Cantor Fitzgerald

€213.18→€204.65

Buy

14.33%

Upside

Reiterated

04/08/26

AbbVie price target lowered to $240 from $250 at Cantor FitzgeraldAbbVie price target lowered to $240 from $250 at Cantor Fitzgerald

Chris Schott

J.P. Morgan

€221.7

Buy

23.86%

Upside

Reiterated

04/07/26

AbbVie should be bought on recent selloff, says JPMorganAbbVie should be bought on recent selloff, says JPMorgan

Louise Chen

Scotiabank

€238.76

Buy

33.38%

Upside

Reiterated

04/06/26

AbbVie (ABBV) Gets a Buy from Scotiabank

Courtney Breen

Bernstein

―

Hold

―

Reiterated

04/03/26

Analysts' Top Healthcare Picks: AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF)

Evan Seigerman

BMO Capital

€220

Buy

22.90%

Upside

Reiterated

04/01/26

AbbVie: Resilient Core, Growing Aesthetics, and Strategic Acquisitions Underpin Buy Rating

Hans Engel

Erste Group

―

Hold

―

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Viridian Therapeutics (NASDAQ: VRDN)

David Amsellem

Piper Sandler

€254.96

Buy

42.43%

Upside

Reiterated

03/26/26

Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)

Mohit Bansal

Wells Fargo

€221.7

Buy

23.86%

Upside

Assigned

03/12/26

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)

Luisa Hector

Berenberg Bank

€234.49

Buy

31.00%

Upside

Reiterated

03/12/26

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Geoff Meacham

Citi

€196.12

Hold

9.57%

Upside

Reiterated

03/10/26

Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors

Matt Phipps

William Blair

―

Buy

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)

Terence Flynn

Morgan Stanley

€229.38→€230.23

Buy

28.62%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nico Chen

DBS

€196.12

Hold

9.57%

Upside

Reiterated

02/25/26

DBS Sticks to Their Hold Rating for AbbVie (ABBV)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

RBC Capital

€221.7

Buy

23.86%

Upside

Reiterated

04/10/26

AbbVie (ABBV) Receives a Buy from RBC Capital

Vamil Divan

Guggenheim

€180.42→€212.32

Buy

18.62%

Upside

Reiterated

04/10/26

AbbVie price target raised to $249 from $242 at GuggenheimAbbVie price target raised to $249 from $242 at Guggenheim

Carter Gould

Cantor Fitzgerald

€213.18→€204.65

Buy

14.33%

Upside

Reiterated

04/08/26

AbbVie price target lowered to $240 from $250 at Cantor FitzgeraldAbbVie price target lowered to $240 from $250 at Cantor Fitzgerald

Chris Schott

J.P. Morgan

€221.7

Buy

23.86%

Upside

Reiterated

04/07/26

AbbVie should be bought on recent selloff, says JPMorganAbbVie should be bought on recent selloff, says JPMorgan

Louise Chen

Scotiabank

€238.76

Buy

33.38%

Upside

Reiterated

04/06/26

AbbVie (ABBV) Gets a Buy from Scotiabank

Courtney Breen

Bernstein

―

Hold

―

Reiterated

04/03/26

Analysts' Top Healthcare Picks: AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF)

Evan Seigerman

BMO Capital

€220

Buy

22.90%

Upside

Reiterated

04/01/26

AbbVie: Resilient Core, Growing Aesthetics, and Strategic Acquisitions Underpin Buy Rating

Hans Engel

Erste Group

―

Hold

―

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Viridian Therapeutics (NASDAQ: VRDN)

David Amsellem

Piper Sandler

€254.96

Buy

42.43%

Upside

Reiterated

03/26/26

Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)

Mohit Bansal

Wells Fargo

€221.7

Buy

23.86%

Upside

Assigned

03/12/26

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)

Luisa Hector

Berenberg Bank

€234.49

Buy

31.00%

Upside

Reiterated

03/12/26

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Geoff Meacham

Citi

€196.12

Hold

9.57%

Upside

Reiterated

03/10/26

Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors

Matt Phipps

William Blair

―

Buy

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)

Terence Flynn

Morgan Stanley

€229.38→€230.23

Buy

28.62%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nico Chen

DBS

€196.12

Hold

9.57%

Upside

Reiterated

02/25/26

DBS Sticks to Their Hold Rating for AbbVie (ABBV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months

xxx

Success Rate

17/23 ratings generated profit

Average Return

+6.44%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +6.44% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

19/20 ratings generated profit

Average Return

+17.14%

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +17.14% per trade.

2 Years

xxx

Success Rate

28/29 ratings generated profit

Average Return

+31.94%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.55% of your transactions generating a profit, with an average return of +31.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4AB has received 26 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 217.83.

Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €2.42 with a range of €2.19 to €2.62. The previous quarter’s EPS was €2.31. 4AB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €12.56B with a range of €12.42B to €12.66B. The previous quarter’s sales results were €14.17B. 4AB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 217.83.

What is DE:4AB’s upside potential, based on the analysts’ average price target?

AbbVie has 21.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AbbVie a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.

What is AbbVie’s share price target?

The average share price target for AbbVie is 217.83. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €256.36 ,and the lowest forecast is €191.20. The average share price target represents 21.69% Increase from the current price of €179.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of AbbVie?

To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AbbVie (4AB) Stock Forecast & Price Target

4AB Analyst Ratings

4AB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

4AB Analyst Recommendation Trends

4AB Financial Forecast

4AB Earnings Forecast

4AB Sales Forecast

4AB Stock Forecast FAQ

Detailed List of Analyst Forecasts